News|Videos|October 10, 2023

EP. 13: Re-Treatment and Scheduling with OnabotulinumtoxinA

Author(s)Benjamin M. Brucker, MD, Eman A. Elkadry, MD, Jenna K. Horton, NP

Please see full Prescribing Information for onabotulinumtoxinA, including Boxed Warning.

Sponsored by AbbVie US Medical Affairs

Episodes in this series

EP. 1 In-Clinic Educational Resource on the OAB Treatment Pathway

EP. 1 In-Clinic Educational Resource on the OAB Treatment Pathway

Experts on OAB

EP. 2 EP. 1: An Introduction of the Speakers

Expert on OAB

EP. 3 EP. 2: The Diagnostic Process of OAB and Initial Patient-Clinician Conversations

Expert on OAB

EP. 4 EP. 3: The Typical Patient with OAB and Common Signs and Symptoms

Expert on OAB

EP. 5 EP. 4: The Role of Urodynamic Testing in OAB Evaluation

Experts on OAB

EP. 6 EP. 5: OAB Treatment: Available Strategies and Rationale for Use

Expert on OAB

EP. 7 EP. 6: Factors Informing Selection of Pharmacologic Treatment for OAB

Expert on OAB

EP. 8 Ep. 7: Defining Pharmacologic Treatment Failure in Patients with OAB and Subsequent Treatment Strategies

Expert on OAB

EP. 9 EP. 8: Patient-Clinician Conversations Regarding Initial Pharmacologic Treatment for OAB

Experts on OAB

EP. 10 EP. 9: Treatment Goals and Educational Resources for Patients on Initial Pharmacologic Therapy for OAB

Expert on OAB

EP. 11 EP. 10: Third-Line OAB Therapies and Patient-Centered Decision-Making

Expert on OAB

EP. 12 EP. 11: Setting Treatment Expectations for Patients with OAB Receiving Third-Line Therapies

Expert on OAB

EP. 13 EP. 12: OAB Patient Monitoring and Followup Considerations in the Third-Line Treatment Setting

Experts on OAB

EP. 14 EP. 13: Re-Treatment and Scheduling with OnabotulinumtoxinA

Expert on OAB

EP. 15 EP. 14: SNM and PTNS for OAB: Device Management and Followup

Expert on OAB

EP. 16 EP. 15: Subsequent Treatment Considerations for Patients with Unsatisfactory Responses to Third-Line Therapy for OAB

This content is intended for US/PR Healthcare Professionals.

The Medical Affairs department of AbbVie Inc. is the sole author and copyright owner of this presentation and has paid Urology Times to host this presentation. AbbVie is solely responsible for all written and oral content within this presentation. © 2023 AbbVie Inc. All rights reserved.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related to this article

Q&A: Where ProACT fits in the male stress urinary incontinence algorithm

November 12th, 2026

Q&A: Where ProACT fits in the male stress urinary incontinence algorithm

Kiran Sury, MD, discusses patient selection, durability, and adverse events with ProACT for male stress urinary incontinence.

Trending on Urology Times

Treatment interruptions in prostate cancer: Balancing PSA kinetics and quality of life

FDA approves durvalumab plus enfortumab vedotin for cisplatin-ineligible MIBC

FDA grants breakthrough therapy designation to 64Cu-SAR-bisPSMA for recurrent prostate cancer imaging

American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing

The UroOnc Minute: The Role of Language in Cancer Care, With Jessica Rett, PhD